A Single Group, Open-Label, Multicenter ,Phase Ib/II Clinical Trials of TQ05105 Tablet in Patients With Glucocorticoid Refractory and Dependent Moderate to Severe Chronic Graft Versus Host Disease (cGVHD).

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rovadicitinib (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions; Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

24 Jul 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
24 Jul 2023 Status changed from recruiting to active, no longer recruiting.
15 Jun 2023 Updated results(At data cutoff September 30, 2022, n=30) assessing safety and efficacy of Jak/Rock Inhibitor Tq05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight